Search results
Delivering on our promise for patients. Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases. An experienced international management team sets the direction for our ...
Apr 3, 2024 · Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses). The transaction will further broaden Genmab’s mid- to late-stage clinical pipeline and strengthen and complement Genmab’s already validated suite of proprietary technology ...
Overview. Epcoritamab (DuoBody ® -CD3xCD20) is an investigational proprietary bispecific antibody created using Genmab’s DuoBody technology, jointly owned by Genmab and AbbVie Inc. It targets CD20 on the B-cells, a validated target that is expressed in a wide variety of B-cell malignancies. Clinical Trials.
A history of accomplishments rooted in science. From our start in Copenhagen in 1999, our continued commitment to oncology has given us purpose and a drive to improve the lives of people with cancer. It is our aspiration for the future that by 2030, our knock-your-socks-off antibody medicines (KYSO antibody medicines ®) are fundamentally ...
- www.marketwatch.com
- › Home
- › Dow Jones Newswires
5 days ago · Genmab GMAB, +1.49% and Pfizer PFE, +0.94% said Monday that the antibody-drug conjugate had been approved to treat patients who have disease progression on or after chemotherapy, meaning it is a ...
February 25 marks Genmab’s 25th anniversary. Over the past quarter-century, Genmab has emerged as a scientific leader in antibody research, working towards the goal of pioneering and revolutionizing the way we treat cancer and other serious diseases. Since our founding in 1999, innovative science has been our core, as we strive to create ...
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the ...
